ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogsGuiqiang Wang, Jinzi J. Wu, Yao Xie et al.|Journal of Hepatology|2022Cited by 20